2020
DOI: 10.1530/erc-20-0157
|View full text |Cite
|
Sign up to set email alerts
|

The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience

Abstract: The ensuing COVID-19 pandemic poses unprecedented and daunting challenges to the routine delivery of oncological and supportive care to patients with breast cancer. Considerations include the infective risk of patients who are inherently immunosuppressed from their malignancy and therapies, long-term oncological outcomes from the treatment decisions undertaken during this extraordinary period, and diverted healthcare resources to support a coordinated whole-of-society outbreak response. In this review,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
32
0
5

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 31 publications
(37 citation statements)
references
References 57 publications
0
32
0
5
Order By: Relevance
“…The European Society for Medical Oncology Guidelines include increasing telehealth appointments (noting in person visits are needed for new cancer patients or urgent infections / post-operative complications) and specific guidance for management and advised that the risk/benefit balance for most patients favored continued administration of systemic therapies and chemotherapies, with additional precautions when possible (e.g., choosing less immunosuppressive therapies, regimens requiring fewer appointments) 26 . Numerous other guidance documents have emerged fluidly including from ASCO and an online resource from ASCO, and others globally 18 , 28 , 29 , 30 , 31 , 32 , 33 .…”
Section: Initial Response: Routine Health Care Deferredmentioning
confidence: 99%
“…The European Society for Medical Oncology Guidelines include increasing telehealth appointments (noting in person visits are needed for new cancer patients or urgent infections / post-operative complications) and specific guidance for management and advised that the risk/benefit balance for most patients favored continued administration of systemic therapies and chemotherapies, with additional precautions when possible (e.g., choosing less immunosuppressive therapies, regimens requiring fewer appointments) 26 . Numerous other guidance documents have emerged fluidly including from ASCO and an online resource from ASCO, and others globally 18 , 28 , 29 , 30 , 31 , 32 , 33 .…”
Section: Initial Response: Routine Health Care Deferredmentioning
confidence: 99%
“…During this COVID-19 pandemic, the uncertainty of when this pandemic might end has a significant psychological impact on individuals (Tsamakis et al, 2020) and may heighten the unknowns faced by CS, raising anxiety levels. Doctors may delay non-urgent routine appointments for cancer surveillance to a later date, which could heighten worry about recurrence (Chan et al, 2020).…”
Section: Cancer Survivorship During Covid-19 As a Double Crisismentioning
confidence: 99%
“…A total of 1.53% (441/28,904) of the included publications were about patients with cancer during the COVID-19 pandemic (eg, [88][89][90][91]). The following authors published the highest number of articles related to this topic: Solange Peters (n=6), Umberto Ricardi (n=5), Conghua Xie (n=5), Giuseppe Curigliano (n=5), and Alessio Cortellini (n=4).…”
Section: Topic 14: Patients With Cancer During the Covid-19 Pandemicmentioning
confidence: 99%